Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244687 | 0.93 | GAA (0.38) | GAAALDH1A1ATMKDM4ERORC | |
| SCHEMBL4240199 | 0.90 | L3MBTL1 (0.43) | GAAALDH1A1KDM4ERORCL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL4243180 | 0.87 | PIK3R2 (0.41) | KDM4ERORCL3MBTL1 | |
| SCHEMBL4240870 | 0.85 | ROCK1 (0.37) | RORC | |
| SCHEMBL4243769 | 0.84 | CD38 (0.40) | ALDH1A1RORC | |
| Trifluoroacetic Acid SCHEMBL4240979 | 0.82 | L3MBTL1 (0.35) | RORCL3MBTL1 | |
| SCHEMBL6082285 | 0.81 | GAA (0.42) | GAAALDH1A1ATMKDM4EHSD17B10 | |
| SCHEMBL4245433 | 0.78 | ADRB2 (0.43) | ALDH1A1KDM4EHSD17B10RORC | |
| SCHEMBL4060598 | 0.78 | SMN1; SMN2 (0.42) | GAAKDM4ERORCL3MBTL1 | |
| SCHEMBL4243183 | 0.77 | PIK3R2 (0.37) | GAAALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| US-7638521-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | IDO1, IDO2, HTR3C | GAA 688/4885ALDH1A1 963/4885ATM 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.